These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35249851)

  • 1. The impact of the modified frailty index on clinical outcomes for patients with stage IV non-small cell lung cancer receiving chemotherapy.
    Mathur S; Prince L; Bucher O; Xue L; Banerji S; Dawe DE
    J Geriatr Oncol; 2022 Jun; 13(5):654-661. PubMed ID: 35249851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.
    Ruiz J; Miller AA; Tooze JA; Crane S; Petty WJ; Gajra A; Klepin HD
    J Geriatr Oncol; 2019 Jan; 10(1):48-54. PubMed ID: 30005982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.
    Raghavan G; Shaverdian N; Chan S; Chu FI; Lee P
    Clin Lung Cancer; 2018 Sep; 19(5):e759-e766. PubMed ID: 29954680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the modified frailty index in predicting toxicity and cancer outcomes for older adults with advanced pancreatic cancer receiving first-line palliative chemotherapy.
    Rittberg R; Zhang H; Lambert P; Kudlovich R; Kim CA; Dawe DE
    J Geriatr Oncol; 2021 Jan; 12(1):112-117. PubMed ID: 32798212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-factor modified frailty index as a prognostic factor of stereotactic radiosurgery for metastatic disease to the brain.
    Lucido T; Rajkumar S; Rogowski B; Meinert J; Elhamdani S; Liang Y; Karlovits S; Yu A; Wegner RE; Shepard MJ
    J Neurosurg; 2024 Apr; 140(4):929-937. PubMed ID: 37856413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
    Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
    Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy.
    Franco I; Chen YH; Chipidza F; Agrawal V; Romano J; Baldini E; Chen A; Colson Y; Hou Y; Kozono D; Wee J; Mak R
    J Geriatr Oncol; 2018 Mar; 9(2):130-137. PubMed ID: 28941581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
    Anouti B; Althouse S; Durm G; Hanna N
    Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.
    Nadler E; Yu E; Ravelo A; Sing A; Forsyth M; Gruschkus S
    Oncologist; 2011; 16(4):486-96. PubMed ID: 21441299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
    Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
    Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
    Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
    Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Targeted Therapy on the Survival of Patients With Advanced-Stage Non-small Cell Lung Cancer in Oncosalud - AUNA.
    Aguilar A; Mas L; Enríquez D; Vallejos C; Gutarra R; Flores CJ
    Cancer Control; 2022; 29():10732748211068637. PubMed ID: 35030060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.